-$0.64 Earnings Per Share Expected for Tricida, Inc. (NASDAQ:TCDA) This Quarter

Equities research analysts expect Tricida, Inc. (NASDAQ:TCDAGet Rating) to announce ($0.64) earnings per share for the current quarter, Zacks reports. Zero analysts have issued estimates for Tricida’s earnings, with the highest EPS estimate coming in at ($0.58) and the lowest estimate coming in at ($0.70). Tricida posted earnings of ($1.06) per share in the same quarter last year, which would suggest a positive year over year growth rate of 39.6%. The firm is scheduled to report its next quarterly earnings results on Monday, January 1st.

According to Zacks, analysts expect that Tricida will report full-year earnings of ($2.35) per share for the current financial year, with EPS estimates ranging from ($2.65) to ($2.04). For the next financial year, analysts forecast that the company will report earnings of ($1.01) per share, with EPS estimates ranging from ($2.05) to $0.03. Zacks’ earnings per share averages are a mean average based on a survey of research firms that follow Tricida.

Tricida (NASDAQ:TCDAGet Rating) last released its earnings results on Tuesday, March 29th. The company reported ($0.92) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($0.24). During the same quarter in the prior year, the company earned ($1.09) earnings per share.

Several equities analysts have weighed in on the company. Zacks Investment Research lowered Tricida from a “buy” rating to a “hold” rating in a report on Thursday, January 20th. The Goldman Sachs Group assumed coverage on Tricida in a report on Tuesday. They set a “buy” rating and a $25.00 price objective for the company. Finally, Needham & Company LLC reissued a “buy” rating and set a $18.00 price objective (down from $20.00) on shares of Tricida in a report on Wednesday, March 30th.

Several large investors have recently bought and sold shares of TCDA. Hsbc Holdings PLC purchased a new stake in shares of Tricida during the third quarter worth $47,000. Jackson Square Capital LLC raised its position in shares of Tricida by 36.6% in the third quarter. Jackson Square Capital LLC now owns 17,978 shares of the company’s stock worth $83,000 after buying an additional 4,820 shares in the last quarter. Barclays PLC raised its position in shares of Tricida by 112.7% in the third quarter. Barclays PLC now owns 20,253 shares of the company’s stock worth $94,000 after buying an additional 10,733 shares in the last quarter. Charles Schwab Investment Management Inc. purchased a new stake in shares of Tricida in the fourth quarter worth $149,000. Finally, Dimensional Fund Advisors LP raised its position in shares of Tricida by 54.3% in the third quarter. Dimensional Fund Advisors LP now owns 49,379 shares of the company’s stock worth $229,000 after buying an additional 17,383 shares in the last quarter. Hedge funds and other institutional investors own 88.47% of the company’s stock.

NASDAQ TCDA traded down $0.33 on Wednesday, hitting $9.31. 15,986 shares of the stock traded hands, compared to its average volume of 338,826. The business’s fifty day moving average is $8.96 and its two-hundred day moving average is $7.81. Tricida has a 12 month low of $3.55 and a 12 month high of $10.92. The firm has a market capitalization of $515.75 million, a price-to-earnings ratio of -2.72 and a beta of 1.10. The company has a debt-to-equity ratio of 584.92, a quick ratio of 4.94 and a current ratio of 4.94.

About Tricida (Get Rating)

Tricida, Inc is a pharmaceutical company. It focuses on the development and commercialization of its product, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease. The company was founded by Gerrit Klaerner and Craig Jon Hawker in 2013 and is headquartered in South San Francisco, CA.

Recommended Stories

Get a free copy of the Zacks research report on Tricida (TCDA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Tricida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tricida and related companies with MarketBeat.com's FREE daily email newsletter.